Atlas Trials

The ASCEND Study: Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Clinical trial NCT05042128 · UNKNOWN

Trial details

NCT number
NCT05042128
Sponsor
Australasian Gastro-Intestinal Trials Group
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Pancreatic Ductal AdenocarcinomaMetastatic Pancreatic Cancer
Start date
2022-04-13
Primary completion
2025-06-01
Enrollment
158

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.